Spago Nanomedical’s CDO on the endometriosis study
First North-listed Spago Nanomedical has recently initiated a phase IIa study with the MRI contrast agent SpagoPix in endometriosis. Paul Hargreaves, Chief Development Officer, visited BioStock’s studio and talked about the disease, the need for better diagnostics and the phase IIa study.
Watch the interview with Spago Nanomedical’s CDO Paul Hargreaves in the link below.
